We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Point Therapeutics (MM) | NASDAQ:POTP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): January 10, 2008
POINT
THERAPEUTICS, INC
.
(Exact
name of registrant as specified in its charter)
DELAWARE |
0-19410 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number)
|
70 WALNUT STREET, WELLESLEY HILLS, MASSACHUSETTS 02481 |
(Address
of Principal Executive Offices)
|
Registrant's telephone number, including
area code: (781) 239-7502
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing
Rule or Standard; Transfer of Listing.
On January 10, 2007, Point Therapeutics, Inc. ("Point") issued a press
release announcing that on January 4, 2007, Point received an additional
notice of non-compliance from the staff of the Listing Qualifications
Department of The NASDAQ Stock Market LLC.
The notice was based upon Point’s failure to solicit proxies and hold an
annual meeting of stockholders prior to December 31, 2007, as required
by NASDAQ Marketplace Rules 4350(g) and 4350(e), respectively. The
notice was issued in accordance with NASDAQ rules and procedures and
notwithstanding the recent decision of the NASDAQ Listing Qualifications
Panel (the "Panel") which granted Point’s request for continued listing
on NASDAQ, pending completion of its proposed merger with DARA
BioSciences, Inc. ("DARA") on or before January 30, 2008.
A copy of the press release is attached as Exhibit 99.1 to this report
(c) Exhibits. |
|
99.1 - Press release issued by Point dated January 10, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
POINT THERAPEUTICS, INC. |
|||
|
|||
January 10, 2008 |
By: /s/ Michael P. Duffy |
||
Name: |
Michael P. Duffy |
||
Title: |
Secretary |
EXHIBIT INDEX
The following exhibit is filed herewith:
Exhibit |
Description |
99.1 |
Press release issued on January 10, 2008. |
1 Year Point Therapeutics (MM) Chart |
1 Month Point Therapeutics (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions